Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that several of its subsidiaries in the United States reached a settlement in principle to resolve claims brought by Ven-A-Care of the Florida Keys, Inc. on behalf of the United States, Texas, Florida, and California under federal and state False Claims Acts. Together with many other pharmaceutical manufacturers, Teva is named in numerous civil lawsuits that relate to drug price reporting by manufacturers in about 15 states…

Excerpt from:
Teva Announces Settlement In Principle Regarding Certain Drug Pricing Lawsuits

Popularity: unranked

You may also like:

• Don’t Let Cupid’s Arrows Make Your Eyes Water, With New Guide To Passionate Safer Sex From THT, UK
• More Than $119 Million Awarded To States And Territories
• BIO Joins Stakeholders In Expressing Concerns With Efforts To Restrict Gene Patenting
• Study Finds That Lower Medicare Fees Do Not Increase Volume Of Patient Care
• First FDA-Approved Stem Cell Trial In Pediatric Cerebral Palsy
• Gaining Market Access By Providing Value For Money
• Chief Medical Officer Mobilises GPs To Support Pandemic (H1N1) 2009 Influenza Vaccinations
• Teva Announces Tentative Approval Of Generic Femara(R) Tablets
• R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study On RK-023
• FDA Approves SAMSCA(TM) (tolvaptan), The First And Only Oral Vasopressin Antagonist To Treat Patients With Clinically Significant Hypervolemic